[go: up one dir, main page]

MX2008001597A - Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento. - Google Patents

Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.

Info

Publication number
MX2008001597A
MX2008001597A MX2008001597A MX2008001597A MX2008001597A MX 2008001597 A MX2008001597 A MX 2008001597A MX 2008001597 A MX2008001597 A MX 2008001597A MX 2008001597 A MX2008001597 A MX 2008001597A MX 2008001597 A MX2008001597 A MX 2008001597A
Authority
MX
Mexico
Prior art keywords
fenofibrate
statin
treatment
related methods
novel formulations
Prior art date
Application number
MX2008001597A
Other languages
English (en)
Inventor
Julius Remenar
Hector Guzman
Orn Almarsson
Carolyn Jordan
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of MX2008001597A publication Critical patent/MX2008001597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invencion proporciona formulaciones novedosas de aceite omega-3 que comprende fenofibrato y una estatina; estas formulaciones son efectivas en volumenes pequenos; tambien se describen metodos relacionados de tratamiento.
MX2008001597A 2005-08-04 2006-08-03 Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento. MX2008001597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70559805P 2005-08-04 2005-08-04
PCT/US2006/030580 WO2007019373A2 (en) 2005-08-04 2006-08-03 Novel formulations comprising fenofibrate and a statin, and related methods of treatment

Publications (1)

Publication Number Publication Date
MX2008001597A true MX2008001597A (es) 2008-04-04

Family

ID=37727947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001597A MX2008001597A (es) 2005-08-04 2006-08-03 Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.

Country Status (12)

Country Link
US (1) US7772277B2 (es)
EP (1) EP1922065A4 (es)
JP (1) JP2009515816A (es)
KR (1) KR20080033410A (es)
CN (1) CN101500555A (es)
AU (1) AU2006278444A1 (es)
BR (1) BRPI0614378A2 (es)
CA (1) CA2617805A1 (es)
IL (1) IL189165A0 (es)
MX (1) MX2008001597A (es)
RU (1) RU2008108078A (es)
WO (1) WO2007019373A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
MX2013000703A (es) * 2010-07-19 2014-07-24 Procaps Sa Aparato y proceso para encapsular capsulas u otras formas de dosificacion solidas dentro de capsulas.
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
CN102357096A (zh) * 2011-09-09 2012-02-22 北京阜康仁生物制药科技有限公司 一种含有他汀类药物锌盐的降血脂组合物
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
KR101719907B1 (ko) * 2015-06-17 2017-03-24 동국대학교 산학협력단 오메가-3 인지질 기반 페노피브레이트 제제 및 이의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
ATE497384T1 (de) * 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
WO1999029300A1 (en) 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
JP2003520767A (ja) 1999-03-31 2003-07-08 アボット・ラボラトリーズ 脂質調整剤を含む新規製剤
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1339429A4 (en) * 2000-11-29 2007-03-14 Smithkline Beecham Corp COMPOSITION CONTAINING STATINS AND CALCIUM FOR IMPROVING CARDIOVASCULAR HEALTH
CA2456732C (en) * 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
IL160077A0 (en) * 2001-08-16 2004-06-20 Teva Pharma Processes for preparing calcium salt forms of statins
AU2003245736A1 (en) 2002-02-14 2003-09-04 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
WO2004002458A1 (en) 2002-06-28 2004-01-08 Shire Laboratories Inc. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10261067A1 (de) 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
MXPA05009242A (es) * 2003-03-17 2006-04-18 Pfizer Prod Inc Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment

Also Published As

Publication number Publication date
KR20080033410A (ko) 2008-04-16
US7772277B2 (en) 2010-08-10
JP2009515816A (ja) 2009-04-16
EP1922065A2 (en) 2008-05-21
BRPI0614378A2 (pt) 2011-03-22
EP1922065A4 (en) 2009-11-11
AU2006278444A1 (en) 2007-02-15
CA2617805A1 (en) 2007-02-15
WO2007019373A2 (en) 2007-02-15
RU2008108078A (ru) 2009-09-10
US20070032546A1 (en) 2007-02-08
CN101500555A (zh) 2009-08-05
WO2007019373A3 (en) 2009-04-23
IL189165A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
ATE376996T1 (de) Antibakterielle mittel
HN2005000477A (es) Compuestos de aminoheteroarilo sustituidos con piraol como inhibidores de proteina quinasa
HN2003000227A (es) Inhibidores de quinasas
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
EA200701918A1 (ru) Белок липокалин
ATE461217T1 (de) Glp-1-verbindungen
AR059155A1 (es) Composiciones que comprenden enzimas y fotoblanqueadores
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
ITMI20030385A1 (it) Composizione cosmetica comprendente poliisoprene.
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
NO20063293L (no) Farmasoytiske forbindelser
DK1713438T3 (da) Medicinsk sæbe
ES2422423T3 (es) Usos cosméticos y farmacéuticos de un extracto de las semillas de Buchholzia coriacea
DE50313053D1 (de) Hydraulischer mitnehmerkipphebel
ITBO20030715A1 (it) Calzatura.
GT200500052A (es) Agente parasiticida
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
DE50308666D1 (de) Gesättigte und ungesättigte heteroarylcycloalkymethyl-amine als antidepressiva
ITRM20030053A1 (it) Associazione di farmaci antidiabetici.
BRPI0717083A2 (pt) Nitrilas alfa, insaturadas como frangrâncias
ES1056367Y (es) Una zapatilla.